MCID: PTT037
MIFTS: 45

Pituitary Tumors malady

Categories: Cancer diseases

Aliases & Classifications for Pituitary Tumors

Aliases & Descriptions for Pituitary Tumors:

Name: Pituitary Tumors 51 52 41
Pituitary Neoplasms 69

Classifications:



Summaries for Pituitary Tumors

NINDS : 51 The pituitary is a small, bean-sized gland that is below the hypothalamus, a structure at the base of the brain, by a thread-like stalk that contains both blood vessels and nerves.  It controls a system of hormones in the body that regulate growth, metabolism, the stress response, and functions of the sex organs via the thyroid gland, adrenal gland, ovaries, and testes.  A pituitary tumor is an abnormal growth of cells within the pituitary gland.  Most pituitary tumors are benign, which means they are non-cancerous, grow slowly and do not spread to other parts of the body; however they can make the pituitary gland produce either too many or too few hormones, which can cause problems in the body. Tumors that make hormones are called functioning tumors, and they can cause a wide array of symptoms depending upon the hormone affected.  Tumors that don’t make hormones are called non-functioning tumors.  Their symptoms are directly related to their growth in size and include headaches, vision problems, nausea, and vomiting.  Diseases related to hormone abnormalities include Cushing’s disease, in which fat builds up in the face, back and chest, and the arms and legs become very thin; and acromegaly, a condition in which the hands, feet, and face are larger than normal.  Pituitary hormones that impact the sex hormones, such as estrogen and testosterone, can make a woman produce breast milk even though she is not pregnant or nursing, or cause a man to lose his sex drive or lower his sperm count.  Pituitary tumors often go undiagnosed because their symptoms resemble those of so many other more common diseases.

MalaCards based summary : Pituitary Tumors, also known as pituitary neoplasms, is related to pituitary adenoma, acth-secreting and neuritis. An important gene associated with Pituitary Tumors is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are Peptide ligand-binding receptors and Pathways in cancer. The drugs Dopamine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are growth/size/body region and endocrine/exocrine gland

MedlinePlus : 41 your pituitary gland is a pea-sized gland at the base of your brain. the pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. pituitary tumors are common, but often they don't cause health problems. most people with pituitary tumors never even know they have them. the most common type of pituitary tumor produces hormones and disrupts the balance of hormones in your body. this can cause endocrine diseases such as cushing's syndrome and hyperthyroidism. symptoms of pituitary tumors include headaches vision problems nausea and vomiting problems caused by the production of too many hormones pituitary tumors are usually curable. treatment is often surgery to remove the tumor. other options include medicines, radiation therapy, and chemotherapy.

Related Diseases for Pituitary Tumors

Diseases related to Pituitary Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
id Related Disease Score Top Affiliating Genes
1 pituitary adenoma, acth-secreting 31.5 GNAS IGF1 PRL SST
2 neuritis 29.5 SST SSTR5
3 prolactin producing pituitary tumor 12.0
4 tsh producing pituitary tumor 12.0
5 empty sella syndrome 11.2
6 pituitary adenoma, growth hormone-secreting 11.1
7 pituitary apoplexy 11.1
8 gigantism 11.1
9 secondary adrenal insufficiency 11.1
10 hormone producing pituitary cancer 10.9
11 posterior pituitary gland neoplasm 10.7
12 pituitary gland disease 10.7
13 pemphigus vegetans 10.3 GH1 SST
14 glaucoma, hereditary adult type 1a 10.3 GH1 PRL
15 oculocutaneous albinism 10.2 SST VEGFA
16 critical congenital heart disease 10.2 GH1 IGF1
17 grin2a-related speech disorders and epilepsy 10.2 GH1 GNAS PRL
18 microtia, hearing impairment, and cleft palate 10.2 GH1 IGF1
19 spondylometaphyseal dysplasia, megarbane-dagher-melike type 10.2 GH1 IGF1
20 lung occult small cell carcinoma 10.2 PRL SST
21 pemphigus foliaceus 10.2 MEN1 SST
22 paranasal sinus cancer, adult 10.2 MEN1 SST
23 primary effusion lymphoma 10.2 GH1 GNAS IGF1
24 idiopathic hypersomnia without long sleep time 10.2 POU1F1 PROP1
25 congenital amputation 10.2 POU1F1 PROP1
26 epidermolysis bullosa simplex, sutosomal recessive 2 10.1 IGF1 SST VEGFA
27 adenoma 10.1
28 acromegaly 10.1
29 glomangiomyoma 10.1 GH1 GNAS PRL SST
30 burning mouth syndrome type 3 10.1 POMC SST
31 renal hypoplasia, bilateral 10.1 POMC SST
32 plasmalogens synthesis deficiency isolated 10.1 GH1 POU1F1 PRL
33 shaver's disease 10.1 GH1 POU1F1 PROP1
34 water-clear cell adenoma 10.1 POMC SST
35 pituitary adenoma 10.1
36 thyroiditis 10.1
37 early-onset glaucoma 10.1 POU1F1 PROP1
38 bowen-conradi syndrome 10.1 MEN1 PRL
39 microvascular complications of diabetes 3 10.1 GH1 IGF1 POU1F1
40 macrocephaly, benign familial 10.1 GH1 POMC
41 edict syndrome 10.1 GH1 IGF1 PRL SST
42 gynandroblastoma 10.1 GH1 IGF1 POU1F1
43 vertebral artery occlusion 10.0 POMC PRL
44 leukemia, acute promyelocytic, somatic 10.0 GNAS MEN1 PRL SST
45 neutropenia, severe congenital, 5, autosomal recessive 10.0 MEN1 SST SSTR5
46 mental retardation, x-linked syndromic, christianson type 10.0 POU1F1 PROP1
47 wheat allergy 10.0 POMC PRL
48 african histoplasmosis 10.0 POMC PRL SST
49 benign shuddering attacks 10.0 GNAS MEN1 SST VEGFA
50 hepatic vascular disease 10.0 POMC VEGFA

Graphical network of the top 20 diseases related to Pituitary Tumors:



Diseases related to Pituitary Tumors

Symptoms & Phenotypes for Pituitary Tumors

MGI Mouse Phenotypes related to Pituitary Tumors:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.14 VEGFA SSTR5 TSHB IGF1 PROP1 MEN1
2 endocrine/exocrine gland MP:0005379 10.13 VEGFA SSTR5 PRL IGF1 PROP1 MEN1
3 homeostasis/metabolism MP:0005376 10.11 VEGFA SST SSTR5 PRL IGF1 PROP1
4 immune system MP:0005387 9.97 VEGFA SST PRL IGF1 MEN1 RB1
5 liver/biliary system MP:0005370 9.73 VEGFA GNAS PRL MEN1 RB1 POMC
6 neoplasm MP:0002006 9.7 VEGFA PRL IGF1 MEN1 RB1 POMC
7 nervous system MP:0003631 9.65 VEGFA SST PRL IGF1 PROP1 MEN1
8 reproductive system MP:0005389 9.23 TSHB VEGFA PRL IGF1 PROP1 MEN1

Drugs & Therapeutics for Pituitary Tumors

Drugs for Pituitary Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
3
Cabergoline Approved Phase 4,Phase 3,Phase 2,Early Phase 1 81409-90-7 54746
4
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
5
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
6
Progesterone Approved, Vet_approved Phase 4,Phase 1,Phase 2 57-83-0 5994
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
11
lanreotide Approved Phase 4,Phase 3 108736-35-2
12
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
13
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
14
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
15
Zinc Approved Phase 4 7440-66-6 32051 23994
16
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
17
Metformin Approved Phase 4 657-24-9 14219 4091
18
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
19
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Liraglutide Approved Phase 4 204656-20-2
23
Cefazolin Approved Phase 4 25953-19-9 656510 33255
24
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
25
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
26
Cefdinir Approved Phase 4 91832-40-5 6915944
27
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
28
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
29
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
30
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
31
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 54575, 6560146 143
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
33
Butyric Acid Experimental Phase 4 107-92-6 264
34 insulin Phase 4,Phase 3,Phase 2,Phase 1
35 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
36 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
37 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Cortisol succinate Phase 4,Phase 3,Phase 2
40 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anesthetics Phase 4,Phase 1
43 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
48 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
49 Hydrocortisone-17-butyrate Phase 4
50 Hypoglycemic Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 228)
id Name Status NCT ID Phase
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4
4 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
5 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Completed NCT01861717 Phase 4
6 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4
7 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4
8 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4
9 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4
10 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
11 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4
12 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4
13 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
14 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
15 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4
16 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4
17 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4
18 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4
19 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4
20 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4
21 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
22 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4
23 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
24 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4
25 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4
26 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4
27 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4
28 Polycystic Ovary Syndrome (PCOS) and Sleep Apnea Terminated NCT00203996 Phase 4
29 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3
30 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3
31 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3
32 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3
33 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3
34 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3
35 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3
36 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3
37 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
38 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3
39 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
40 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3
41 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3
42 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Completed NCT01653743 Phase 3
43 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3
44 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3
45 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3
46 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3
47 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3
48 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3
49 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3
50 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3

Search NIH Clinical Center for Pituitary Tumors

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Pituitary Tumors

Anatomical Context for Pituitary Tumors

MalaCards organs/tissues related to Pituitary Tumors:

39
Pituitary, Brain, Thyroid, Testes, Breast, Hypothalamus, Ovary

Publications for Pituitary Tumors

Articles related to Pituitary Tumors:

(show top 50) (show all 823)
id Title Authors Year
1
Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report. ( 28072724 )
2017
2
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. ( 28120505 )
2017
3
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. ( 27655724 )
2016
4
Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary tumors: systematic review and meta-analysis of randomized and non-randomized controlled trials. ( 27598981 )
2016
5
Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. ( 26721946 )
2016
6
Learning curve for the transsphenoidal endoscopic endonasal approach to pituitary tumors. ( 27332969 )
2016
7
Therapeutic innovations in endocrine diseases - partA 3A : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. ( 27242211 )
2016
8
The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. ( 27815769 )
2016
9
Magnetic Resonance Imaging of Pituitary Tumors. ( 27003878 )
2016
10
Letter to the Editor: Pituitary tumors and cavernous sinus extension. ( 26848910 )
2016
11
Refractory pituitary adenoma: a novel classification for pituitary tumors. ( 27845901 )
2016
12
cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. ( 27267386 )
2016
13
The Utility of Magnetic Resonance Imaging in Assessing Patients With Pituitary Tumors Compressing the Anterior Visual Pathway. ( 27391942 )
2016
14
MucinA 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine. ( 26935338 )
2016
15
Alteration of Pituitary Tumor Transforming Gene-1 Regulates Trophoblast Invasion via the Integrin/Rho-Family Signaling Pathway. ( 26900962 )
2016
16
Advances in Gamma Knife radiosurgery for pituitary tumors. ( 27341278 )
2016
17
Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up. ( 27635138 )
2016
18
The role of microRNAs in the pathogenesis of pituitary tumors. ( 26709756 )
2016
19
The Clinical Utility of TIMP3 Expression in ACTH-Secreting Pituitary Tumor. ( 26676407 )
2016
20
Endoscopic Approach to Pituitary Tumors. ( 26626930 )
2016
21
Histopathological and immunohistochemical characterization of spontaneous pituitary tumors in dwarfs derived from Wistar Hannover GALAS rats. ( 26597119 )
2016
22
Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. ( 27600151 )
2016
23
Molecular markers in pituitary tumors. ( 27254269 )
2016
24
Multimodal Navigation in Endoscopic Transsphenoidal Resection of Pituitary Tumors using Image-based Vascular and Cranial Nerve Segmentation: A Prospective Validation Study. ( 27302558 )
2016
25
Editorial: Systems Biological Aspects of Pituitary Tumors. ( 27445988 )
2016
26
Adenoid Cystic Carcinoma Metastatic to the Pituitary: A Case Report and Discussion of Potential Diagnostic Value of Magnetic Resonance Elastography in Pituitary Tumors. ( 27018011 )
2016
27
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. ( 26983879 )
2016
28
Radiation Therapy in the Management of Pituitary Tumors. ( 26626931 )
2016
29
Snare technique for the remodeling of the redundant arachnoid pouch to prevent cerebrospinal fluid rhinorrhea and hematoma collection during transsphenoidal surgery for suprasellar-extended pituitary tumors. ( 26967785 )
2016
30
Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors. ( 27639583 )
2016
31
A Case of Optic Neuritis Concomitant with Pituitary Tumor During Pregnancy. ( 27373939 )
2016
32
Pituitary tumor transforming gene-1 in non-small cell lung cancer: Clinicopathological and immunohistochemical analysis. ( 27829547 )
2016
33
Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. ( 25627474 )
2016
34
Etiology of Pituitary Tumors: A Case Control Study. ( 26956811 )
2016
35
MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN. ( 27465551 )
2016
36
Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. ( 26763580 )
2016
37
Assessment of Environmental and Hereditary Influence on Development of Pituitary Tumors Using Dermatoglyphic Traits and Their Potential as Screening Markers. ( 26999178 )
2016
38
Resection of pituitary tumors: endoscopic versus microscopic. ( 27161249 )
2016
39
The role of temozolomide in the treatment of aggressive pituitary tumors. ( 25772801 )
2015
40
Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line. ( 26284494 )
2015
41
Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. ( 26391562 )
2015
42
Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors. ( 26562326 )
2015
43
Expression of the Pituitary Tumor Transforming Gene (PTTG1) in Pheochromocytoma as a Potential Marker for Distinguishing Benign Versus Malignant Tumors. ( 25871022 )
2015
44
Early morphological recovery of the optic chiasm is associated with excellent visual outcome in patients with compressive chiasmal syndrome caused by pituitary tumors. ( 24938320 )
2015
45
Aggressive Pituitary Tumors. ( 25571935 )
2015
46
Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. ( 26322309 )
2015
47
Cabergoline use for pituitary tumors and valvular disorders. ( 25732645 )
2015
48
Melatonin and cortisol profiles in patients with pituitary tumors. ( 25666777 )
2015
49
Hemostatic Disorders in Hormonally Active Pituitary Tumors. ( 26285071 )
2015
50
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors. ( 25792375 )
2015

Variations for Pituitary Tumors

Expression for Pituitary Tumors

Search GEO for disease gene expression data for Pituitary Tumors.

Pathways for Pituitary Tumors

GO Terms for Pituitary Tumors

Cellular components related to Pituitary Tumors according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 GH1 IGF1 POMC SST TSHB VEGFA
2 extracellular region GO:0005576 9.23 GH1 GNAS IGF1 POMC PRL SST
3 endosome lumen GO:0031904 9.16 GH1 PRL
4 secretory granule GO:0030141 9.13 POMC PRL VEGFA

Biological processes related to Pituitary Tumors according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.85 MEN1 POU1F1 PROP1 RB1 VEGFA
2 regulation of multicellular organism growth GO:0040014 9.58 IGF1 PRL
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 GH1 IGF1 VEGFA
4 positive regulation of receptor internalization GO:0002092 9.57 GH1 VEGFA
5 peptide hormone processing GO:0016486 9.56 POMC TSHB
6 tissue homeostasis GO:0001894 9.55 GNAS RB1
7 positive regulation of JAK-STAT cascade GO:0046427 9.54 GH1 PRL
8 myoblast differentiation GO:0045445 9.52 IGF1 RB1
9 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.51 GH1 IGF1
10 positive regulation of epithelial cell proliferation GO:0050679 9.5 IGF1 PRL VEGFA
11 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.49 GH1 PRL
12 positive regulation of transcription regulatory region DNA binding GO:2000679 9.48 IGF1 RB1
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 IGF1
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 GH1 IGF1 VEGFA
15 adenohypophysis development GO:0021984 9.37 POU1F1 PROP1
16 negative regulation of cell proliferation GO:0008285 9.35 MEN1 POU1F1 RB1 SST SSTR5
17 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.17 IGF1 MEN1 POMC POU1F1 PROP1 RB1
18 somatotropin secreting cell differentiation GO:0060126 9.16 POU1F1 PROP1

Molecular functions related to Pituitary Tumors according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 GH1 IGF1 VEGFA
2 insulin-like growth factor receptor binding GO:0005159 9.16 GNAS IGF1
3 hormone activity GO:0005179 9.1 GH1 IGF1 POMC PRL SST TSHB
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....